Comment
doi: 10.1056/NEJMc1515613.
Treatment of Advanced Renal-Cell Carcinoma
Affiliations
- PMID: 26962912
- DOI: 10.1056/NEJMc1515613
Item in Clipboard
Comment
Treatment of Advanced Renal-Cell Carcinoma
N Engl J Med.
.
No abstract available
Comment in
-
Treatment of Advanced Renal-Cell Carcinoma.N Engl J Med. 2016 Mar 3;374(9):889-90. doi: 10.1056/NEJMc1515613. N Engl J Med. 2016. PMID: 26962911 No abstract available.
Comment on
-
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Similar articles
-
Treatment of Advanced Renal-Cell Carcinoma.N Engl J Med. 2016 Mar 3;374(9):888-9. doi: 10.1056/NEJMc1515613. N Engl J Med. 2016. PMID: 26962913 No abstract available.
-
Treatment of Advanced Renal-Cell Carcinoma.N Engl J Med. 2016 Mar 3;374(9):889-90. doi: 10.1056/NEJMc1515613. N Engl J Med. 2016. PMID: 26962911 No abstract available.
-
Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma.Urology. 2016 Mar;89:8-9. doi: 10.1016/j.urology.2015.12.003. Epub 2015 Dec 23. Urology. 2016. PMID: 26723186 No abstract available.
-
Targeted therapy in renal cell carcinoma.Curr Opin Urol. 2008 Sep;18(5):481-7. doi: 10.1097/MOU.0b013e32830a70cf. Curr Opin Urol. 2008. PMID: 18670271 Review.
-
[Drug treatment of metastatic renal cell carcinoma].Dtsch Med Wochenschr. 2013 Aug;138(31-32):1567-70. doi: 10.1055/s-0033-1343291. Epub 2013 Jul 8. Dtsch Med Wochenschr. 2013. PMID: 23836159 Review. German. No abstract available.
Cited by
-
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma.BMC Cancer. 2025 Jul 25;25(1):1220. doi: 10.1186/s12885-025-14654-3. BMC Cancer. 2025. PMID: 40713516 Free PMC article.
-
H1/pAIM2 nanoparticles exert anti-tumour effects that is associated with the inflammasome activation in renal carcinoma.J Cell Mol Med. 2018 Nov;22(11):5670-5681. doi: 10.1111/jcmm.13842. Epub 2018 Aug 30. J Cell Mol Med. 2018. PMID: 30160343 Free PMC article.
-
Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.Drug Des Devel Ther. 2017 Apr 11;11:1175-1182. doi: 10.2147/DDDT.S110209. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28442891 Free PMC article. Review.
-
Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.Drug Des Devel Ther. 2017 Sep 21;11:2801-2811. doi: 10.2147/DDDT.S109640. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 29033542 Free PMC article. Review.
-
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.Immunotherapy. 2024;16(18-19):1095-1103. doi: 10.1080/1750743X.2024.2385881. Epub 2024 Aug 19. Immunotherapy. 2024. PMID: 39155821 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
